Equities

Poolbeg Pharma PLC

Poolbeg Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)7.75
  • Today's Change0.150 / 1.97%
  • Shares traded1.25m
  • 1 Year change-20.51%
  • Beta2.9034
Data delayed at least 20 minutes, as of Nov 22 2024 16:28 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-4.38m
  • Incorporated2021
  • Employees8.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Synairgen plc0.00-6.92m9.38m36.00--0.9751-----0.0344-0.03440.000.04750.00----0.00-47.18-54.01-54.24-60.02------------0.00------52.35---26.64--
IXICO PLC6.00m-1.87m11.12m89.00--0.578--1.85-0.0386-0.03860.12410.20760.4725--3.5467,415.73-14.694.35-16.585.3346.9062.09-31.106.61----0.03120.00-22.894.32-214.15--92.12--
OptiBiotix Health PLC569.00k-2.98m12.00m5.00--1.63--21.09-0.0317-0.03170.00610.07520.06341.351.07113,800.00-33.2516.82-34.8517.5247.9853.03-524.43183.495.36-2.030.00100.1440.924.60-178.82------
Incanthera PLC0.00-1.55m16.37m7.00---------0.0189-0.01890.00-0.00610.00----0.00-852.34-115.31---153.87---------------------12.76------
Hemogenyx Pharmaceuticals PLC0.00-5.18m21.38m17.00--6.68-----0.0042-0.00420.000.00230.00----0.00-77.79-82.19-85.95-95.97-----------19.940.4794-------68.14--36.68--
Shield Therapeutics PLC20.88m-36.17m23.07m73.00--42.64--1.10-0.0477-0.04770.02740.00070.47234.061.69286,068.50-81.80-56.68-136.41-67.4434.6552.20-173.18-365.890.8968-15.290.9736--137.951.9533.13---2.50--
Arecor Therapeutics PLC4.90m-8.67m28.88m50.00--4.61--5.90-0.283-0.2830.160.16580.3213--1.6797,980.00-56.84---89.06-------176.89--1.27--0.0523--90.30--7.62------
Sareum Holdings Plc0.00-3.42m32.43m5.00--13.28-----0.0422-0.04220.000.01960.00-------142.89-81.13-209.37-96.44-------23,877.73---163.36---------7.14------
Skinbiotherapeutics PLC161.65k-2.88m36.26m11.00--8.28--224.34-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Poolbeg Pharma PLC0.00-4.38m38.00m8.00--3.05-----0.0088-0.00880.000.02490.00----0.00-29.11---30.18--------------0.00------16.11------
Futura Medical PLC8.40m-3.75m100.75m12.00--12.82--12.00-0.0126-0.01260.02720.02590.85385,710.277.20699,850.80-38.14-79.25-47.43-127.2267.70---44.68-914.373.75--0.00-------11.40--219.68--
Data as of Nov 22 2024. Currency figures normalised to Poolbeg Pharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

16.18%Per cent of shares held by top holders
HolderShares% Held
Schroder Investment Management Ltd.as of 08 Mar 202324.99m5.00%
Hargreaves Lansdown Asset Management Ltd.as of 01 Nov 202418.92m3.78%
Jarvis Investment Management Ltd.as of 01 Nov 202414.90m2.98%
IG Markets Ltd.as of 01 Nov 20247.73m1.55%
Bank Julius B�r & Co. AGas of 01 Nov 20244.62m0.93%
HSBC Global Asset Management (UK) Ltd.as of 01 Nov 20243.46m0.69%
Evelyn Partners Investment Management LLPas of 01 Nov 20242.79m0.56%
Schroder Investment Management (Switzerland) AGas of 01 Nov 20241.65m0.33%
Evelyn Partners Investment Management Services Ltd.as of 01 Nov 20241.05m0.21%
iDealing.com Ltd.as of 01 Nov 2024788.00k0.16%
More ▼
Data from 31 Dec 2023 - 05 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.